Allogene Therapeutics (ALLO) Accumulated Expenses (2017 - 2026)

Allogene Therapeutics has disclosed Accumulated Expenses across 10 years of filings, most recently posting $23.4 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $23.4 million, down 6.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.4 million (down 6.28% YoY), and the FY2025 annual result was $28.2 million, down 6.26% from the prior year.
• Accumulated Expenses came in at $23.4 million for Q1 2026 at Allogene Therapeutics, down from $28.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $44.6 million in Q1 2023 to a low of $23.4 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $28.2 million (2025), against an average of $31.1 million.
• Across the five-year window, Accumulated Expenses jumped 60.73% in 2023 and sank 44.94% in 2024, its largest moves.
• Allogene Therapeutics' Accumulated Expenses stood at $39.7 million in 2022, then declined by 21.54% to $31.2 million in 2023, then decreased by 3.38% to $30.1 million in 2024, then decreased by 6.26% to $28.2 million in 2025, then decreased by 17.16% to $23.4 million in 2026.
• The last three Accumulated Expenses figures came in at $23.4 million (Q1 2026), $28.2 million (Q4 2025), and $28.1 million (Q3 2025), per Business Quant data.